InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.04
(
-0.11%
)
Bitcoin
66,289.76
(
-0.52%
)
Post# of 4856
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

$$$eeker

Send PM Follow Ignore
Followers 29
Posts 2503
Boards Moderated 0
Alias Born 04/09/2010

$$$eeker

Re: was CUIN2 post# 3285

Monday, 12/15/2014 1:04:12 PM

Monday, December 15, 2014 1:04:12 PM

Post# of 4856
$CUR NSI-566 spinal cord-derived stem cell therapy for the treatment of ALS
Neuralstem announced the last patient was treated in the current multicenter Phase II ALS clinical trial. This dose escalating trial treated 15 ambulatory patients in five different cohorts. Each of the three patients in the final cohort received a total of 40 injections of 400,000 cells in both the cervical and lumbar regions. The six-month observation period and data lock is scheduled to conclude in late January 2015 at which time the company anticipates providing its Phase II ALS results. - See more at: http://investor.neuralstem.com/index.php?s=43&item=196#sthash.hnWQLyZK.dpuf

http://investor.neuralstem.com/index.php?s=43&item=196
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up